Trials / Active Not Recruiting
Active Not RecruitingNCT07305831
A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)
A Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of MK-8507 on the QTc Interval in Healthy Adult Participants
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 62 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
Researchers are looking for new treatments for HIV-1 (human immunodeficiency virus type 1) that are safe, well-tolerated, and can be taken less often. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. Ulonivirine (MK-8507) is a study medicine designed to treat HIV-1 The goal of this study is to learn if ulonivirine does not increase the QT interval (a measure of heart rhythm on an electrocardiogram) above a certain amount. Researchers also want to learn what happens to the amount of ulonivirine in a healthy person's body over time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ulonivirine | Oral tablet |
| DRUG | Moxifloxacin | Oral tablet |
| DRUG | Ulonivirine Placebo | Oral tablet |
| DRUG | Moxifloxacin Placebo | Oral tablet |
Timeline
- Start date
- 2026-01-22
- Primary completion
- 2026-04-09
- Completion
- 2026-04-09
- First posted
- 2025-12-26
- Last updated
- 2026-03-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07305831. Inclusion in this directory is not an endorsement.